



Current Trends in Rheumatoid Arthritis: Knowledge Gaps and Awareness Strategies

Akhtar Ali¹; Muhammad Akram^{1*}; Fethi Ahmet Ozdemir²; Gawel Sołowski²; Adonis Sfera³; Eisa Yazeed Ghazwani⁴

¹Department of Eastern Medicine, Government College University Faisalabad-Pakistan.

²Department of Molecular Biology and Genetics, Faculty of Science and Art, Bingol University, Bingol, 1200, Türkiye.

³Department of Psychiatry, Patton State Hospital, USA.

⁴Department of Family and Community Medicine, College of Medicine, Najran University, Najran, Kingdom of Saudi Arabia.

***Corresponding Author(s): Muhammad Akram**

Department of Eastern Medicine, Government
College University Faisalabad-Pakistan.

Email: makram_0451@hotmail.com

Abstract

Rheumatoid Arthritis (RA) is a common chronic inflammatory disease, but considerable gaps remain in our understanding of its origin, early detection, and appropriate treatment. Despite advances in biologic medications, many patients continue to receive late diagnoses and insufficient care. This study investigates current trends in RA research, identifies important knowledge gaps, and examines measures to increase public and healthcare awareness. Improving education and early intervention are crucial to improving patient outcomes and reducing the burden of the disease.

Received: Dec 11, 2024

Accepted: Jan 06, 2025

Published Online: Jan 13, 2025

Journal:

Annals of Community Medicine and Primary Health Care

Publisher: MedDocs Publishers LLC

Online edition: <http://meddocsonline.org/>

Copyright: © Akram M (2025). *This Article is distributed under the terms of Creative Commons Attribution 4.0 International License*

Keywords: Rheumatoid arthritis; Disease pathogenesis; Public awareness; Disease burden; Healthcare professionals; Awareness campaigns.

Introduction

It is a condition that affects many joints throughout the body, primarily the hands and feet [1]. The tiny joints in the hands and feet are the most commonly impacted, but any synovial membrane-lined joint might be affected [2]. Skin, pulmonary, cardiac, ocular, neurological, and hematological symptoms are all examples of extra-articular involvement. RA affects people in different ways throughout the world. In America, RA affects roughly 15% of the population [3]. The prevalence of RA in the rest of society in the United States is believed to be between 0.5 % and 1.0 %. Nearly 26,000 suspected cases are diagnosed each year in Europe.

The bulk of incidence studies in the North American and Northern European regions suggest a pervasiveness of 0.5 % to 1.1 % [4]. According to studies, pervasiveness is between 0.3 % and 0.7 % in southern European countries [5]. In addition, studies in developing countries show that disease prevalence is significantly lower (between 0.1 % and 0.5 percent) [6]. Some native Americans have a higher prevalence of RA, while RA is rare in some rural African locations. According to RA researchers, the prevalence of the disease in Europe and North America may be higher than in Asia [7]. It is unclear whether this geographic changeability is due to hereditary, ecological, or investigational variation styles.



Cite this article: Ali A, Akram M, Ozdemir FA, Sołowski G, Sfera A, et al. Current Trends in Rheumatoid Arthritis: Knowledge Gaps and Awareness Strategies. *Ann Community Med Prim Health Care*. 2025; 3(1): 1026.

In different parts of the same state, the pervasiveness varies. According to reports, the prevalence of RA in Karachi residents could be 0.142 %, whereas the prevalence rate in northern Pakistan is predicted to be 0.55 % [8]. RA was far more popular in the north, with other Pakistani citizens in England adopting it at a comparable rate [9].

Pathophysiology of RA

Joint degradation is caused by macrophages, which are similar to synoviocytes, and fibroblasts, which are similar to synoviocytes. IgM and IgA are two types of antibodies. Rheumatoid factors are pathogenic indicators that target the IgG Fc fragment [10]. Antibodies directed against citrullinated peptides are another type of antibody. Genetic factors are responsible for 50% of the chance of having RA.

Age and gender

The beginning usually occurs between the ages of 30 and 50, with a peak in adults between the ages of 40 and 60. In observational studies in Europe, North America, and Asia, the prevalence of RA in women is well established, with greater men to women proportions [11] (2-5.6:1).

Hormonal and reproductive factors

The investigations were, however, heterogeneous, with different doses and durations of OC exposure [12]. Longer OC use was found to be protective in numerous evaluations [13].

Nonhormonal reproductive factors

Chronic infections

Chronic arthritis is linked to Lyme disease, which is caused by the bacteria *Borrelia burgdorferi* [14]. There have been reports of RA cases detected following Lyme disease. Many disorders, such as obesity, diabetes, and inflammatory bowel disease, have been linked to dysbiotic microbiota. Oral and gut dysbiotic microbiota have also been identified in RA patients. Prevotella species are more common in people who have recently been diagnosed with RA [15].

Smoking

Occupational exposure

Obesity

Clinical features of RA

- Morning stiffness
- Inflammation of joints
- Warmness on the joints
- Joints pain
- Fatigue

Diagnosis

- Swollen joints especially in hands
- Tenderness on the metatarsophalangeal joints
- The symptoms lasted around 14 days
- Raised ESR
- Raised CRP

- Multiple numbers of swollen joints

Radiological procedures (Burmester and Pope 2017)

Treatment

Glucocorticoids

Anti-inflammatory and disease-modifying effects of glucocorticoids have been discovered [16]. They are useful in attaining remission and decreasing radiographic development in early rheumatoid arthritis when used in conjunction with DMARDs, and they are relatively safe when used at low doses [17]. Low-dose glucocorticoids (usually prednisone 10-15 mg/day) are provided in combination with one or more DMARD and discontinued as soon as clinically practicable as part of the first-line treatment [18]. When switching DMARDs for symptom control, they are frequently utilized as a bridging therapy [19].

Hydroxychloroquine

Its anti-inflammatory/immunomodulatory properties are the result of its interference with "antigen presentation" in macrophages and other antigen-introducing cells. It lowers the organization of peptide-MHC protein complexes, which is required for CD4+ T-cell stimulation, and as a result, the insusceptible reactivity to autoantigens is downregulated. Hydroxychloroquine inhibits lupus-related mucocutaneous manifestations, may reduce the risk of flares, allows for a reduction in steroid dosage, reduces organ damage, and prevents the thrombotic effects of antiphospholipid antibodies. The calming activity of hydroxychloroquine differs from that of other calming prescriptions, therefore it is more effective when used in combination with other calming medications (Moutsopoulos and Zampeli 2021).

Conclusion

Addressing information gaps in rheumatoid arthritis is critical to improving early diagnosis, treatment effectiveness and patient outcomes. Increased public and healthcare provider awareness, as well as continued research into new medications, will be critical to reducing the burden of the disease and improving long-term treatment techniques.

References

1. Francia P, Anichini R, Seghieri G, De Bellis A, Gulisano M. History, prevalence and assessment of limited joint mobility, from stiff hand syndrome to diabetic foot ulcer prevention: a narrative review of the literature. *Current Diabetes Reviews*. 2018; 14(5): 411-26.
2. Rothschild BM, Surmik D, Bertozzo F. Mechanically Derived Phenomena. In *Modern Paleopathology, The Study of Diagnostic Approach to Ancient Diseases, their Pathology and Epidemiology: Let there be light, the light of science and critical thinking*. Cham: Springer International Publishing. 2023; 167-227.
3. Cross M, Smith E, Hoy D, Carmona L, Wolfe F, et al. The global burden of rheumatoid arthritis: Estimates from the global burden of disease 2010 study. *Annals of the rheumatic diseases*. 2014; 73(7): 1316-22.
4. Marlon JR, Bartlein PJ, Daniau AL, Harrison SP, Maezumi SY, et al. Global biomass burning: a synthesis and review of Holocene paleofire records and their controls. *Quaternary Science Reviews*. 2013; 65: 5-25.
5. Casas M, Chatzi L, Carsin AE, Amiano P, Guxens M, et al. Maternal pre-pregnancy overweight and obesity, and child neuropsychology.

- chological development: two Southern European birth cohort studies. *International journal of epidemiology*. 2013; 42(2): 506-17.
6. Sheridan JF, Aurelian L, Barbour G, Santosham M, et al. Traveler's diarrhea associated with rotavirus infection: Analysis of virus-specific immunoglobulin classes. *Infection and Immunity*. 1981; 31(1): 419-29.
 7. Akkoc N. Are spondyloarthropathies as common as rheumatoid arthritis worldwide? A review. *Current rheumatology reports*. 2008; 10(5): 371-8.
 8. Varghese RP. Welfare consequences of coresiding with the mother-in-law in patriarchal joint families for women and children: Evidence from India and Bangladesh. *The University of Chicago*. 2009.
 9. Blakemore K, Boneham M. Age, Race and Ethnicity: A Comparative Approach. *Rethinking Ageing Series*. Open University Press, 1900 Frost Road, Suite 101, Bristol, PA 19007 (paperback: ISBN-0-335-19086-3; clothbound: ISBN-0-335-19234-3); Open University Press, Celtic Court, 22 Ballmoor, Buckingham, England, United Kingdom MK18 1XW. 1994.
 10. Lewis BJ, Branch DR. Mouse models of rheumatoid arthritis for studies on immunopathogenesis and preclinical testing of Fc receptor-targeting biologics. *Pharmacology*. 2020; 105(11-12): 618-29.
 11. Almutairi KB, Nossent JC, Preen DB, Keen HI, Inderjeeth CA. The prevalence of rheumatoid arthritis: A systematic review of population-based studies. *The Journal of rheumatology*. 2021; 48(5): 669-76.
 12. Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: A meta-analysis. *European journal of cancer*. 2010; 46(12): 2275-84.
 13. Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. *Physiological reviews*. 2008; 88(2): 581-609.
 14. Steere AC, Strle F, Wormser GP, Hu LT, Branda JA, et al. Lyme borreliosis. *Nature reviews Disease primers*. 2016; 2(1): 1-9.
 15. Berthelot JM, Bandiaky ON, Le Goff B, Amador G, Chaux AG, et al. Another look at the contribution of oral microbiota to the pathogenesis of rheumatoid arthritis: a narrative review. *Microorganisms*. 2021; 10(1): 59.
 16. Bermas BL. Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy. *Current opinion in rheumatology*. 2014; 26(3): 334-40.
 17. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: Update. *Arthritis & Rheumatism*. 2002; 46(2): 328-46.
 18. Hetland ML. Modern treatment strategies in rheumatoid arthritis. *Dan Med Bull*. 2011; 58(11): B4320.
 19. Van Ouwkerk L, Boers M, Emery P, De Jong PH, Landewé RB, et al. Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis. *Annals of the rheumatic diseases*. 2023; 82(4): 468-75.